Scarica l'app Stockscreener
4.355
1.75%
0.075
Pre-mercato:
4.36
0.005
+0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$4.28
Aprire:
$4.32
Volume 24 ore:
884.36K
Relative Volume:
0.69
Capitalizzazione di mercato:
$604.98M
Reddito:
$62.04M
Utile/perdita netta:
$-533.34M
Rapporto P/E:
-1.111
EPS:
-3.92
Flusso di cassa netto:
$-473.07M
1 W Prestazione:
-14.77%
1M Prestazione:
-22.92%
6M Prestazione:
-52.20%
1 anno Prestazione:
-48.58%
Intervallo 1D:
$4.305
$4.50
Intervallo di 1 settimana:
$4.155
$5.09
Portata 52W:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Confronta VIR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
4.355 | 594.56M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Vir Biotechnology’s Q2 2025: Unraveling Contradictions in ECLIPSE Trials, HDV Prevalence, and T-Cell Strategies - AInvest
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $12 to $31 - 富途牛牛
Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Call Transcript - Insider Monkey
Vir Biotechnology’s Earnings Call Highlights Progress and Challenges - TipRanks
Vir Biotechnology (VIR.O) Plunges 14.5%: What’s Driving the Intraday Swoon? - AInvest
Vir Biotechnology's 12.4% Intraday Drop: A Technical and Order-Flow Deep Dive - AInvest
Earnings call transcript: Vir Biotech Q2 2025 results fall short, stock dips - Investing.com
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - BioSpace
Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum - MSN
Vir Biotechnology 2025 Q2 Earnings Losses Narrow 19.8% as Net Income Declines - AInvest
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Vir Biotechnology Reports Q2 2025 Financial Results - TipRanks
Vir Biotechnology's Q2 2025 Performance and Future Outlook: A Contrarian's Playbook for a Biotech Underdog - AInvest
Vir Biotechnology: A High-Conviction Play in Hepatitis Delta and Next-Gen Oncology Innovation - AInvest
Transcript : Vir Biotechnology, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Vir Biotechnology Q2 Earnings Fall Short of Estimates, Revenue Lags Behind - AInvest
Vir Biotechnology Q2 2025 Earnings Call Transcript - MarketBeat
Vir Biotechnology, Inc. SEC 10-Q Report - TradingView
Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss - MarketScreener
Vir Biotechnology Q2 revenue misses expectations, net loss narrows - MarketScreener
Vir Biotechnology reports Q2 EPS (80c), consensus (72c) - TipRanks
Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance - StreetInsider
Press Release: Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results - 富途牛牛
Vir Biotechnology enrolls first participant in ECLIPSE 3 trial - TipRanks
Vir Biotechnology successfully initiates all trials in Eclipse registrational program - MarketScreener
Vir Biotechnology completes initiation of hepatitis delta program By Investing.com - Investing.com Nigeria
Vir Biotechnology enrolls first patient in ECLIPSE 3 hepatitis delta trial - StreetInsider
Vir Biotechnology Director SATO VICKI L Sells 22000 Shares at $4.99/Share. - AInvest
How strong is Vir Biotechnology Inc. company’s balance sheetAchieve breakthrough results with expert guidance - Jammu Links News
Is Vir Biotechnology Inc. a good long term investmentMaximize gains with data-driven stock picks - Jammu Links News
Vir Biotechnology initiates second pivotal trial in its global ECLIPSE registrational program for chronic hepatitis delta - European AIDS Treatment Group
Is Vir Biotechnology Inc. stock overvalued or undervaluedMaximize your returns with expert insights - Jammu Links News
What analysts say about Vir Biotechnology Inc. stockMassive stock growth - Jammu Links News
How does Vir Biotechnology Inc. generate profit in a changing economyConsistent double returns - Jammu Links News
Should I hold or sell Vir Biotechnology Inc. stock in 2025Discover high-impact stocks for your portfolio - Jammu Links News
Vir Biotechnology Inc. Stock Analysis and ForecastCapitalize on market trends with confidence - Jammu Links News
What are the latest earnings results for Vir Biotechnology Inc.Unlock exclusive stock market forecasts - Jammu Links News
What are Vir Biotechnology Inc. company’s key revenue driversUnmatched market performance - Jammu Links News
How many analysts rate Vir Biotechnology Inc. as a “Buy”Consistent triple returns - Jammu Links News
Published on: 2025-08-03 07:23:25 - Jammu Links News
When is Vir Biotechnology Inc. stock expected to show significant growthBuild a winning investment portfolio - Jammu Links News
Why is Vir Biotechnology Inc. stock attracting strong analyst attentionExceptional return forecasts - Jammu Links News
What are analysts’ price targets for Vir Biotechnology Inc. in the next 12 monthsUnlock powerful portfolio optimization tools - Jammu Links News
How does Vir Biotechnology Inc. compare to its industry peersBreakout Stocks Tracker For Consistent Profits - jammulinksnews.com
Vir Biotechnology Inc. Recovery Gathers Momentum on Chart SignalsLow Risk Equity Screener With Results Shared - metal.it
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta - BioSpace
Vir Biotechnology shares rise 1.38% after-hours after initiating second pivotal trial in global ECLIPSE program for chronic hepatitis delta. - AInvest
Vir Biotech enrolls first patient in hepatitis delta virus trial - Investing.com Australia
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):